US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

4.72

-0.0700-1.46%

Volume:762.00K

Turnover:3.62M

Market Cap:283.97M

PE:-6.55

High:4.84

Open:4.81

Low:4.68

Close:4.79

52wk High:7.20

52wk Low:1.14

Shares:60.16M

Float Shares:48.48M

Volume Ratio:0.91

T/O Rate:1.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7210

EPS(LYR):-0.9389

ROE:-64.31%

ROA:-28.94%

PB:5.77

PE(LYR):-5.03

Loading ...

Overview Company News Filings

Aldeyra Therapeutics Inc - No Approved Treatment for Primary Vitreoretinal Lymphoma in EU

THOMSON REUTERS

Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal Lymphoma

THOMSON REUTERS

Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa

Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected to Start in 2025

THOMSON REUTERS

Aldeyra Therapeutics Receives Fast Track Designation for Adx‑2191 for the Treatment of Retinitis Pigmentosa

THOMSON REUTERS

Michael Alfieri, Principal Financial Officer, Reports Acquisition of Common Shares of Aldeyra Therapeutics Inc

Stephen Machatha, Chief Development Officer, Reports Disposal of Aldeyra Therapeutics Inc. Common Shares

Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Aldeyra Therapeutics Unveils Innovative Therapies for Immune-Mediated and Metabolic Diseases in Latest Presentation

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Aldeyra Therapeutics Secures Orphan Designation from European Medicines Agency for ADX-2191 to Treat Retinitis Pigmentosa

Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected in 2025

THOMSON REUTERS

Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Inherited Retinal Dystrophies Including Retinitis Pigmentosa

THOMSON REUTERS

Aldeyra Therapeutics Announces FDA Acceptance of Reproxalap NDA for Dry Eye Disease with PDUFA Target Date Set for December 2025

BRIEF-Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191

Aldeyra Therapeutics Resubmits New Drug Application for Reproxalap to FDA for Dry Eye Disease Treatment

Aldeyra Therapeutics Inc. Concluded Annual Stockholders Meeting

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

CORRECTED-US FDA approves Alcon's new dry-eye drug (May 28)

Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALDX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALDX\",,,,,undefined,":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":4.72,"timestamp":1765481080657,"preClose":4.79,"halted":0,"volume":762000,"delay":0,"floatShares":48481525,"shares":60162773,"eps":-0.720975,"marketStatus":"Trading","change":-0.07,"latestTime":"12-11 14:24:58 EST","open":4.81,"high":4.835,"low":4.675,"amount":3615286.1399999997,"amplitude":0.033403,"askPrice":4.73,"askSize":1503,"bidPrice":4.72,"bidSize":1201,"shortable":3,"etf":0,"ttmEps":-0.720975,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":4.79,"preHourTrading":{"tag":"盘前","latestPrice":4.8,"preClose":4.79,"latestTime":"09:29 EST","volume":1109,"amount":5324.3996053,"timestamp":1765463355022},"postHourTrading":{"tag":"盘后","latestPrice":4.8067,"preClose":4.79,"latestTime":"18:17 EST","volume":17304,"amount":82903.0169,"timestamp":1765408635559},"volumeRatio":0.910994,"impliedVol":3.0876,"impliedVolPercentile":0.972},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALDX\",,,,,undefined,":{"symbol":"ALDX","floatShares":48481525,"roa":"-28.94%","roe":"-64.31%","lyrEps":-0.938919,"volumeRatio":0.910994,"shares":60162773,"dividePrice":0,"high":4.835,"amplitude":0.033403,"preClose":4.79,"low":4.675,"week52Low":1.14,"pbRate":"5.77","week52High":7.2,"institutionHeld":0,"latestPrice":4.72,"committee":-0.111686,"eps":-0.720975,"divideRate":0,"volume":762000,"delay":0,"ttmEps":-0.720975,"open":4.81,"prevYearClose":4.99,"prevWeekClose":4.7,"prevMonthClose":5.48,"prevQuarterClose":5.22,"fiveDayClose":4.88,"twentyDayClose":5.3,"sixtyDayClose":4.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALDX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"ALDX","fiscalQuarterEnding":"2025/09","expectedEps":-0.17,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-08-07","symbol":"ALDX","fiscalQuarterEnding":"2025/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2025-05-14","symbol":"ALDX","fiscalQuarterEnding":"2025/03","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-02-28","symbol":"ALDX","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-07","symbol":"ALDX","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALDX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALDX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1712466000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALDX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALDX","date":"2025-12-10","current":-6.567495,"percent":0.49147,"low":-21.345025,"twenty":-9.617736,"median":-6.63393,"eighty":-4.457992,"high":-1.518068,"avg":-7.380149,"sd":3.692875,"marketCap":288179682},"quantilePoints":[{"date":"2020-12-11","current":-6.863595,"twenty":-7.450247,"median":-5.870146,"eighty":-2.937247,"marketCap":270577818},{"date":"2020-12-18","current":-7.415046,"twenty":-7.450247,"median":-5.905071,"eighty":-2.967933,"marketCap":292317212},{"date":"2020-12-24","current":-7.159015,"twenty":-7.482285,"median":-5.930417,"eighty":-2.992865,"marketCap":282223922},{"date":"2020-12-31","current":-6.755274,"twenty":-7.482285,"median":-5.9325,"eighty":-3.013003,"marketCap":266307580},{"date":"2021-01-08","current":-10.152606,"twenty":-7.490821,"median":-5.962176,"eighty":-3.073374,"marketCap":400237777},{"date":"2021-01-15","current":-15.486387,"twenty":-7.503288,"median":-5.991987,"eighty":-3.09508,"marketCap":610506996},{"date":"2021-01-22","current":-14.555387,"twenty":-7.556909,"median":-6.007552,"eighty":-3.124689,"marketCap":573804958},{"date":"2021-01-29","current":-13.26447,"twenty":-7.591549,"median":-6.053967,"eighty":-3.144412,"marketCap":522914201},{"date":"2021-02-05","current":-14.910685,"twenty":-7.624996,"median":-6.078755,"eighty":-3.15008,"marketCap":587811589},{"date":"2021-02-12","current":-15.040961,"twenty":-7.693335,"median":-6.132709,"eighty":-3.183005,"marketCap":592947353},{"date":"2021-02-19","current":-15.100177,"twenty":-7.767064,"median":-6.142149,"eighty":-3.201241,"marketCap":595281792},{"date":"2021-02-26","current":-14.519857,"twenty":-7.796919,"median":-6.16163,"eighty":-3.220941,"marketCap":572404295},{"date":"2021-03-05","current":-13.240783,"twenty":-7.828557,"median":-6.177517,"eighty":-3.243557,"marketCap":521980426},{"date":"2021-03-12","current":-15.751579,"twenty":-7.873355,"median":-6.190523,"eighty":-3.266425,"marketCap":591530524},{"date":"2021-03-19","current":-15.072198,"twenty":-7.896823,"median":-6.205642,"eighty":-3.310684,"marketCap":566017227},{"date":"2021-03-26","current":-14.040545,"twenty":-7.935871,"median":-6.232712,"eighty":-3.406836,"marketCap":527274812},{"date":"2021-04-01","current":-15.462213,"twenty":-7.956092,"median":-6.233579,"eighty":-3.452595,"marketCap":580663749},{"date":"2021-04-09","current":-15.147684,"twenty":-7.959625,"median":-6.233579,"eighty":-3.440211,"marketCap":568852037},{"date":"2021-04-16","current":-14.280718,"twenty":-7.959625,"median":-6.233579,"eighty":-3.440211,"marketCap":536294199},{"date":"2021-04-23","current":-13.419823,"twenty":-7.959625,"median":-6.233579,"eighty":-3.440211,"marketCap":503964407},{"date":"2021-04-30","current":-19.261089,"twenty":-7.959625,"median":-6.233579,"eighty":-3.440211,"marketCap":723325716},{"date":"2021-05-07","current":-18.45361,"twenty":-7.959625,"median":-6.233579,"eighty":-3.440211,"marketCap":719237413},{"date":"2021-05-14","current":-17.950868,"twenty":-8.047151,"median":-6.233579,"eighty":-3.440211,"marketCap":699642804},{"date":"2021-05-21","current":-17.344619,"twenty":-8.094651,"median":-6.233579,"eighty":-3.440211,"marketCap":676014011},{"date":"2021-05-28","current":-18.512756,"twenty":-8.112232,"median":-6.233579,"eighty":-3.440211,"marketCap":721542661},{"date":"2021-06-04","current":-18.690195,"twenty":-8.112232,"median":-6.233579,"eighty":-3.440211,"marketCap":728458405},{"date":"2021-06-11","current":-18.246599,"twenty":-8.112232,"median":-6.233579,"eighty":-3.440211,"marketCap":711169045},{"date":"2021-06-18","current":-17.625564,"twenty":-8.112232,"median":-6.233579,"eighty":-3.440211,"marketCap":686963939},{"date":"2021-06-25","current":-16.960169,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":661029898},{"date":"2021-07-02","current":-16.146909,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":629332736},{"date":"2021-07-09","current":-15.939897,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":621264368},{"date":"2021-07-16","current":-14.076792,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":548649052},{"date":"2021-07-23","current":-13.411398,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":522715011},{"date":"2021-07-30","current":-13.160027,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":512917706},{"date":"2021-08-06","current":-12.248303,"twenty":-8.131581,"median":-6.233579,"eighty":-3.440211,"marketCap":568224823},{"date":"2021-08-13","current":-11.587244,"twenty":-8.140064,"median":-6.233579,"eighty":-3.440211,"marketCap":537556885},{"date":"2021-08-20","current":-10.352436,"twenty":-8.213456,"median":-6.233579,"eighty":-3.440211,"marketCap":480271490},{"date":"2021-08-27","current":-11.275424,"twenty":-8.254758,"median":-6.233579,"eighty":-3.440211,"marketCap":523090876},{"date":"2021-09-03","current":-11.499935,"twenty":-8.345275,"median":-6.233579,"eighty":-3.440211,"marketCap":533506402},{"date":"2021-09-10","current":-10.976076,"twenty":-8.427687,"median":-6.233579,"eighty":-3.440211,"marketCap":509203508},{"date":"2021-09-17","current":-10.689202,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":495894779},{"date":"2021-09-24","current":-10.601892,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":491844297},{"date":"2021-10-01","current":-11.063386,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":513253990},{"date":"2021-10-08","current":-10.527055,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":488372455},{"date":"2021-10-15","current":-10.402327,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":482586051},{"date":"2021-10-22","current":-10.01567,"twenty":-8.455414,"median":-6.233579,"eighty":-3.440211,"marketCap":464648201},{"date":"2021-10-29","current":-9.915577,"twenty":-8.562247,"median":-6.233579,"eighty":-3.440211,"marketCap":528638155},{"date":"2021-11-05","current":-9.741237,"twenty":-8.719765,"median":-6.233579,"eighty":-3.440211,"marketCap":519343418},{"date":"2021-11-12","current":-9.610482,"twenty":-8.980277,"median":-6.233579,"eighty":-3.440211,"marketCap":512372366},{"date":"2021-11-19","current":-8.640717,"twenty":-9.110949,"median":-6.233579,"eighty":-3.440211,"marketCap":460670392},{"date":"2021-11-26","current":-8.368311,"twenty":-9.110949,"median":-6.233579,"eighty":-3.440211,"marketCap":446147366},{"date":"2021-12-03","current":-7.507508,"twenty":-9.110949,"median":-6.233579,"eighty":-3.440211,"marketCap":400254603},{"date":"2021-12-10","current":-7.551093,"twenty":-9.110949,"median":-6.241878,"eighty":-3.440211,"marketCap":402578287},{"date":"2021-12-17","current":-7.670952,"twenty":-9.110949,"median":-6.266923,"eighty":-3.440211,"marketCap":408968419},{"date":"2021-12-23","current":-4.543731,"twenty":-9.110949,"median":-6.280316,"eighty":-3.440211,"marketCap":242244077},{"date":"2021-12-31","current":-4.358495,"twenty":-9.110949,"median":-6.266923,"eighty":-3.440211,"marketCap":232368420},{"date":"2022-01-07","current":-4.195052,"twenty":-9.093068,"median":-6.249319,"eighty":-3.452595,"marketCap":223654604},{"date":"2022-01-14","current":-4.118778,"twenty":-9.093068,"median":-6.223021,"eighty":-3.452595,"marketCap":219588156},{"date":"2022-01-21","current":-3.541278,"twenty":-9.093068,"median":-6.205642,"eighty":-3.452595,"marketCap":188799341},{"date":"2022-01-28","current":-3.73741,"twenty":-9.093068,"median":-6.185758,"eighty":-3.452595,"marketCap":199255920},{"date":"2022-02-04","current":-3.857268,"twenty":-9.093068,"median":-6.170324,"eighty":-3.452595,"marketCap":205646051},{"date":"2022-02-11","current":-4.195052,"twenty":-9.075186,"median":-6.166862,"eighty":-3.46498,"marketCap":223654604},{"date":"2022-02-18","current":-4.195052,"twenty":-9.075186,"median":-6.16163,"eighty":-3.46498,"marketCap":223654604},{"date":"2022-02-25","current":-4.445665,"twenty":-9.075186,"median":-6.141595,"eighty":-3.46498,"marketCap":237015788},{"date":"2022-03-04","current":-3.813683,"twenty":-9.075186,"median":-6.117618,"eighty":-3.46498,"marketCap":203322367},{"date":"2022-03-11","current":-4.467458,"twenty":-9.075186,"median":-6.062118,"eighty":-3.46498,"marketCap":238177630},{"date":"2022-03-18","current":-4.977647,"twenty":-9.075186,"median":-6.025624,"eighty":-3.46498,"marketCap":287589876},{"date":"2022-03-25","current":-4.877088,"twenty":-9.075186,"median":-5.991661,"eighty":-3.46498,"marketCap":281779980},{"date":"2022-04-01","current":-4.736306,"twenty":-9.075186,"median":-5.957149,"eighty":-3.46498,"marketCap":273646125},{"date":"2022-04-08","current":-4.756418,"twenty":-9.075186,"median":-5.926721,"eighty":-3.46498,"marketCap":274808104},{"date":"2022-04-14","current":-4.585468,"twenty":-9.075186,"median":-5.888378,"eighty":-3.46498,"marketCap":264931280},{"date":"2022-04-22","current":-3.559772,"twenty":-9.075186,"median":-5.867027,"eighty":-3.46498,"marketCap":205670336},{"date":"2022-04-29","current":-3.097908,"twenty":-9.075186,"median":-5.867027,"eighty":-3.402943,"marketCap":178985577},{"date":"2022-05-06","current":-2.497002,"twenty":-9.075186,"median":-5.867027,"eighty":-3.321629,"marketCap":157997040},{"date":"2022-05-13","current":-2.294293,"twenty":-9.075186,"median":-5.867027,"eighty":-3.266425,"marketCap":145170712},{"date":"2022-05-20","current":-2.625998,"twenty":-9.075186,"median":-5.867027,"eighty":-3.244531,"marketCap":166159249},{"date":"2022-05-27","current":-2.856349,"twenty":-9.075186,"median":-5.867027,"eighty":-3.224387,"marketCap":180734622},{"date":"2022-06-03","current":-2.810279,"twenty":-9.075186,"median":-5.867027,"eighty":-3.211282,"marketCap":177819547},{"date":"2022-06-10","current":-3.289408,"twenty":-9.075186,"median":-5.867027,"eighty":-3.206383,"marketCap":208136322},{"date":"2022-06-17","current":-3.086699,"twenty":-9.075186,"median":-5.867027,"eighty":-3.18876,"marketCap":195309994},{"date":"2022-06-24","current":-3.390762,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":214549486},{"date":"2022-07-01","current":-3.501331,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":221545665},{"date":"2022-07-08","current":-4.137099,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":261773694},{"date":"2022-07-15","current":-4.349021,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":275183037},{"date":"2022-07-22","current":-4.809723,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":304333783},{"date":"2022-07-29","current":-4.64387,"twenty":-9.093068,"median":-5.867443,"eighty":-3.168117,"marketCap":293839514},{"date":"2022-08-05","current":-6.104108,"twenty":-9.093068,"median":-5.870146,"eighty":-3.168117,"marketCap":403595962},{"date":"2022-08-12","current":-6.589261,"twenty":-9.093068,"median":-5.921076,"eighty":-3.168117,"marketCap":435673676},{"date":"2022-08-19","current":-6.12175,"twenty":-9.093068,"median":-5.952123,"eighty":-3.168117,"marketCap":404762425},{"date":"2022-08-26","current":-6.342274,"twenty":-9.093068,"median":-5.991334,"eighty":-3.168117,"marketCap":419343204},{"date":"2022-09-02","current":-6.12175,"twenty":-9.093068,"median":-6.029449,"eighty":-3.168117,"marketCap":404762425},{"date":"2022-09-09","current":-5.795374,"twenty":-9.093068,"median":-6.029449,"eighty":-3.168117,"marketCap":383182872},{"date":"2022-09-16","current":-5.548387,"twenty":-9.025282,"median":-5.99944,"eighty":-3.168117,"marketCap":366852399},{"date":"2022-09-23","current":-4.798605,"twenty":-8.995212,"median":-5.973134,"eighty":-3.168117,"marketCap":317277751},{"date":"2022-09-30","current":-4.710396,"twenty":-8.995212,"median":-5.939818,"eighty":-3.168117,"marketCap":311445439},{"date":"2022-10-07","current":-4.710396,"twenty":-8.995212,"median":-5.902555,"eighty":-3.168117,"marketCap":311445439},{"date":"2022-10-14","current":-4.586902,"twenty":-8.995212,"median":-5.866612,"eighty":-3.168117,"marketCap":303280203},{"date":"2022-10-21","current":-4.639828,"twenty":-8.995212,"median":-5.852475,"eighty":-3.168117,"marketCap":306779590},{"date":"2022-10-28","current":-4.939741,"twenty":-8.995212,"median":-5.828027,"eighty":-3.168117,"marketCap":326609449},{"date":"2022-11-04","current":-4.710396,"twenty":-8.995212,"median":-5.81681,"eighty":-3.168117,"marketCap":311445439},{"date":"2022-11-11","current":-5.244292,"twenty":-8.995212,"median":-5.79593,"eighty":-3.168117,"marketCap":340234053},{"date":"2022-11-18","current":-4.68466,"twenty":-8.995212,"median":-5.756072,"eighty":-3.168117,"marketCap":303926804},{"date":"2022-11-25","current":-4.928371,"twenty":-8.995212,"median":-5.745438,"eighty":-3.168117,"marketCap":319738025},{"date":"2022-12-02","current":-5.885161,"twenty":-8.995212,"median":-5.725248,"eighty":-3.168117,"marketCap":381811708},{"date":"2022-12-09","current":-5.542161,"twenty":-8.995212,"median":-5.698344,"eighty":-3.168117,"marketCap":359558878},{"date":"2022-12-16","current":-5.704634,"twenty":-8.995212,"median":-5.678973,"eighty":-3.168117,"marketCap":370099692},{"date":"2022-12-23","current":-5.957371,"twenty":-8.995212,"median":-5.670218,"eighty":-3.168117,"marketCap":386496514},{"date":"2022-12-30","current":-6.282319,"twenty":-8.995212,"median":-5.670218,"eighty":-3.168117,"marketCap":407578142},{"date":"2023-01-06","current":-6.300372,"twenty":-8.995212,"median":-5.670218,"eighty":-3.168117,"marketCap":408749344},{"date":"2023-01-13","current":-5.821977,"twenty":-8.995212,"median":-5.670218,"eighty":-3.168117,"marketCap":377712503},{"date":"2023-01-20","current":-5.704634,"twenty":-8.995212,"median":-5.654125,"eighty":-3.168117,"marketCap":370099692},{"date":"2023-01-27","current":-5.497029,"twenty":-8.995212,"median":-5.64145,"eighty":-3.168117,"marketCap":356630875},{"date":"2023-02-03","current":-5.578266,"twenty":-8.995212,"median":-5.627776,"eighty":-3.168117,"marketCap":361901282},{"date":"2023-02-10","current":-5.704634,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":370099692},{"date":"2023-02-17","current":-6.417714,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":416362154},{"date":"2023-02-24","current":-6.462845,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":419290158},{"date":"2023-03-03","current":-6.751688,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":438029383},{"date":"2023-03-10","current":-6.780825,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":420578193},{"date":"2023-03-17","current":-7.130255,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":442251442},{"date":"2023-03-24","current":-8.527973,"twenty":-8.995212,"median":-5.622757,"eighty":-3.168117,"marketCap":528944440},{"date":"2023-03-31","current":-9.377937,"twenty":-9.03249,"median":-5.625267,"eighty":-3.171112,"marketCap":581663155},{"date":"2023-04-06","current":-9.189057,"twenty":-9.300198,"median":-5.625267,"eighty":-3.171112,"marketCap":569947885},{"date":"2023-04-14","current":-9.746255,"twenty":-9.376048,"median":-5.614915,"eighty":-3.162128,"marketCap":604507932},{"date":"2023-04-21","current":-9.632927,"twenty":-9.490154,"median":-5.614915,"eighty":-3.162128,"marketCap":597478770},{"date":"2023-04-28","current":-8.546861,"twenty":-9.503657,"median":-5.614915,"eighty":-3.159134,"marketCap":530115967},{"date":"2023-05-05","current":-10.001447,"twenty":-9.575046,"median":-5.614915,"eighty":-3.159134,"marketCap":608608276},{"date":"2023-05-12","current":-9.999554,"twenty":-9.632927,"median":-5.614915,"eighty":-3.159134,"marketCap":608493091},{"date":"2023-05-19","current":-9.289121,"twenty":-9.741237,"median":-5.614915,"eighty":-3.159134,"marketCap":565261777},{"date":"2023-05-26","current":-8.855949,"twenty":-9.741237,"median":-5.614915,"eighty":-3.159134,"marketCap":538902420},{"date":"2023-06-01","current":-9.135104,"twenty":-9.741237,"median":-5.614915,"eighty":-3.159134,"marketCap":555889561},{"date":"2023-06-09","current":-11.445352,"twenty":-9.781881,"median":-5.614915,"eighty":-3.157705,"marketCap":696472801},{"date":"2023-06-16","current":-10.463496,"twenty":-9.813088,"median":-5.614915,"eighty":-3.157705,"marketCap":636724924},{"date":"2023-06-23","current":-7.460175,"twenty":-9.820861,"median":-5.614643,"eighty":-3.156277,"marketCap":453966712},{"date":"2023-06-30","current":-7.604565,"twenty":-9.8233,"median":-5.614371,"eighty":-3.154848,"marketCap":462753165},{"date":"2023-07-05","current":-7.681573,"twenty":-9.8233,"median":-5.614371,"eighty":-3.154848,"marketCap":467439273},{"date":"2023-07-12","current":-7.566061,"twenty":-9.828178,"median":-5.614371,"eighty":-3.151991,"marketCap":460410111},{"date":"2023-07-21","current":-7.691199,"twenty":-9.853303,"median":-5.607073,"eighty":-3.151991,"marketCap":468025036},{"date":"2023-07-28","current":-7.354288,"twenty":-9.859787,"median":-5.602694,"eighty":-3.151991,"marketCap":447523314},{"date":"2023-08-04","current":-8.914643,"twenty":-9.859787,"median":-5.607073,"eighty":-3.151991,"marketCap":464079132},{"date":"2023-08-11","current":-8.576968,"twenty":-9.859787,"median":-5.614371,"eighty":-3.151991,"marketCap":446500377},{"date":"2023-08-18","current":-8.160501,"twenty":-9.859787,"median":-5.627776,"eighty":-3.151991,"marketCap":424819912},{"date":"2023-08-25","current":-8.278687,"twenty":-9.859787,"median":-5.64145,"eighty":-3.151991,"marketCap":430972476},{"date":"2023-09-01","current":-8.396874,"twenty":-9.859787,"median":-5.654125,"eighty":-3.151991,"marketCap":437125041},{"date":"2023-09-08","current":-8.126733,"twenty":-9.859787,"median":-5.669809,"eighty":-3.151991,"marketCap":423062037},{"date":"2023-09-15","current":-7.834081,"twenty":-9.859787,"median":-5.67577,"eighty":-3.151991,"marketCap":407827116},{"date":"2023-09-22","current":-6.967379,"twenty":-9.859787,"median":-5.680702,"eighty":-3.151991,"marketCap":362708311},{"date":"2023-09-29","current":-7.04617,"twenty":-9.818422,"median":-5.680702,"eighty":-3.151991,"marketCap":366810021},{"date":"2023-10-06","current":-6.550912,"twenty":-9.79123,"median":-5.680702,"eighty":-3.151991,"marketCap":341027847},{"date":"2023-10-13","current":-6.06691,"twenty":-9.757165,"median":-5.680702,"eighty":-3.151991,"marketCap":315831631},{"date":"2023-10-20","current":-1.868473,"twenty":-9.63787,"median":-5.670013,"eighty":-3.147213,"marketCap":97269111},{"date":"2023-10-27","current":-1.76717,"twenty":-9.610534,"median":-5.656112,"eighty":-3.146519,"marketCap":91995484},{"date":"2023-11-03","current":-2.352475,"twenty":-9.552867,"median":-5.640939,"eighty":-3.141046,"marketCap":122465326},{"date":"2023-11-10","current":-3.031754,"twenty":-9.474158,"median":-5.618836,"eighty":-3.121982,"marketCap":138526005},{"date":"2023-11-17","current":-3.205548,"twenty":-9.474158,"median":-5.609485,"eighty":-3.113197,"marketCap":146466986},{"date":"2023-11-24","current":-3.257043,"twenty":-9.474158,"median":-5.596319,"eighty":-3.113197,"marketCap":148819869},{"date":"2023-11-30","current":-3.566012,"twenty":-9.4779,"median":-5.583547,"eighty":-3.112073,"marketCap":162937169},{"date":"2023-12-08","current":-4.171075,"twenty":-9.4779,"median":-5.571605,"eighty":-3.112073,"marketCap":190583548},{"date":"2023-12-15","current":-3.836359,"twenty":-9.4779,"median":-5.542161,"eighty":-3.112073,"marketCap":175289807},{"date":"2023-12-22","current":-4.312686,"twenty":-9.4779,"median":-5.506055,"eighty":-3.112073,"marketCap":197053978},{"date":"2023-12-29","current":-4.647401,"twenty":-9.481641,"median":-5.501078,"eighty":-3.110949,"marketCap":212347719},{"date":"2024-01-05","current":-4.299812,"twenty":-9.481641,"median":-5.488003,"eighty":-3.109785,"marketCap":196465757},{"date":"2024-01-12","current":-4.11958,"twenty":-9.481641,"median":-5.478976,"eighty":-3.109785,"marketCap":188230665},{"date":"2024-01-19","current":-3.913601,"twenty":-9.481641,"median":-5.467949,"eighty":-3.108621,"marketCap":178819132},{"date":"2024-01-26","current":-3.913601,"twenty":-9.481641,"median":-5.450232,"eighty":-3.109785,"marketCap":178819132},{"date":"2024-02-02","current":-4.106707,"twenty":-9.481641,"median":-5.407252,"eighty":-3.109785,"marketCap":187642444},{"date":"2024-02-09","current":-4.158201,"twenty":-9.481641,"median":-5.379653,"eighty":-3.109785,"marketCap":189995328},{"date":"2024-02-16","current":-4.634528,"twenty":-9.481641,"median":-5.324759,"eighty":-3.109785,"marketCap":211759498},{"date":"2024-02-23","current":-4.557286,"twenty":-9.481641,"median":-5.303943,"eighty":-3.109785,"marketCap":208230173},{"date":"2024-03-01","current":-4.660275,"twenty":-9.481641,"median":-5.258729,"eighty":-3.110949,"marketCap":212935940},{"date":"2024-03-08","current":-6.070569,"twenty":-9.481641,"median":-5.239043,"eighty":-3.110949,"marketCap":227904411},{"date":"2024-03-15","current":-4.345508,"twenty":-9.481641,"median":-5.197793,"eighty":-3.110949,"marketCap":163141277},{"date":"2024-03-22","current":-4.565137,"twenty":-9.481641,"median":-5.119395,"eighty":-3.110949,"marketCap":171386684},{"date":"2024-03-28","current":-4.831828,"twenty":-9.481641,"median":-5.094682,"eighty":-3.110949,"marketCap":181398965},{"date":"2024-04-05","current":-7.349713,"twenty":-9.481641,"median":-5.090845,"eighty":-3.109785,"marketCap":275926673},{"date":"2024-04-12","current":-6.902612,"twenty":-9.481641,"median":-5.090845,"eighty":-3.109785,"marketCap":259141379},{"date":"2024-04-19","current":-6.243726,"twenty":-9.481641,"median":-5.090845,"eighty":-3.109785,"marketCap":234405156},{"date":"2024-04-26","current":-6.235414,"twenty":-9.481641,"median":-5.094682,"eighty":-3.110949,"marketCap":234093086},{"date":"2024-05-03","current":-8.335346,"twenty":-9.481641,"median":-5.094682,"eighty":-3.110949,"marketCap":250134998},{"date":"2024-05-10","current":-7.800775,"twenty":-9.481641,"median":-5.10734,"eighty":-3.110949,"marketCap":234093086},{"date":"2024-05-17","current":-8.097759,"twenty":-9.481641,"median":-5.129896,"eighty":-3.110949,"marketCap":243005260},{"date":"2024-05-24","current":-7.503791,"twenty":-9.481641,"median":-5.203531,"eighty":-3.110949,"marketCap":225180913},{"date":"2024-05-31","current":-7.642383,"twenty":-9.481641,"median":-5.241941,"eighty":-3.110949,"marketCap":229339927},{"date":"2024-06-07","current":-7.642383,"twenty":-9.481641,"median":-5.305153,"eighty":-3.110949,"marketCap":229339927},{"date":"2024-06-14","current":-7.384998,"twenty":-9.481641,"median":-5.329065,"eighty":-3.110949,"marketCap":221616043},{"date":"2024-06-21","current":-6.890024,"twenty":-9.481641,"median":-5.379653,"eighty":-3.109785,"marketCap":206762421},{"date":"2024-06-28","current":-6.553443,"twenty":-9.481641,"median":-5.411021,"eighty":-3.109785,"marketCap":196661958},{"date":"2024-07-05","current":-6.315856,"twenty":-9.481641,"median":-5.451898,"eighty":-3.109785,"marketCap":189532219},{"date":"2024-07-12","current":-7.642383,"twenty":-9.481641,"median":-5.473758,"eighty":-3.109785,"marketCap":229339927},{"date":"2024-07-19","current":-7.563188,"twenty":-9.481641,"median":-5.488003,"eighty":-3.109785,"marketCap":226963347},{"date":"2024-07-26","current":-8.216552,"twenty":-9.481641,"median":-5.497029,"eighty":-3.109785,"marketCap":246570129},{"date":"2024-08-02","current":-5.515431,"twenty":-9.481641,"median":-5.515082,"eighty":-3.109785,"marketCap":208866751},{"date":"2024-08-09","current":-8.002474,"twenty":-9.481641,"median":-5.528652,"eighty":-3.127395,"marketCap":303049910},{"date":"2024-08-16","current":-7.955401,"twenty":-9.481641,"median":-5.567862,"eighty":-3.145451,"marketCap":301267263},{"date":"2024-08-23","current":-8.739957,"twenty":-9.481641,"median":-5.583547,"eighty":-3.16394,"marketCap":330978039},{"date":"2024-08-30","current":-9.030243,"twenty":-9.481641,"median":-5.596319,"eighty":-3.200147,"marketCap":341971026},{"date":"2024-09-06","current":-9.61866,"twenty":-9.601765,"median":-5.614371,"eighty":-3.211282,"marketCap":364254107},{"date":"2024-09-13","current":-9.461749,"twenty":-9.614963,"median":-5.638441,"eighty":-3.236619,"marketCap":358311952},{"date":"2024-09-20","current":-9.242073,"twenty":-9.614963,"median":-5.669809,"eighty":-3.255733,"marketCap":349992935},{"date":"2024-09-27","current":-8.630119,"twenty":-9.614963,"median":-5.701177,"eighty":-3.315207,"marketCap":326818530},{"date":"2024-10-04","current":-8.379061,"twenty":-9.614963,"median":-5.733627,"eighty":-3.370379,"marketCap":317311082},{"date":"2024-10-11","current":-8.426135,"twenty":-9.614963,"median":-5.795374,"eighty":-3.465597,"marketCap":319093728},{"date":"2024-10-18","current":-8.943942,"twenty":-9.614963,"median":-5.821408,"eighty":-3.555727,"marketCap":338702840},{"date":"2024-10-25","current":-8.355524,"twenty":-9.614963,"median":-5.849056,"eighty":-3.579019,"marketCap":316419759},{"date":"2024-11-01","current":-8.410443,"twenty":-9.614963,"median":-5.944281,"eighty":-3.662938,"marketCap":318499513},{"date":"2024-11-08","current":-7.338075,"twenty":-9.614963,"median":-5.991334,"eighty":-3.682919,"marketCap":328713780},{"date":"2024-11-15","current":-5.596612,"twenty":-9.614963,"median":-6.055473,"eighty":-3.740104,"marketCap":250703807},{"date":"2024-11-22","current":-6.447403,"twenty":-9.614963,"median":-6.101793,"eighty":-3.806317,"marketCap":288815550},{"date":"2024-11-29","current":-6.513871,"twenty":-9.614963,"median":-6.111934,"eighty":-3.821794,"marketCap":291793030},{"date":"2024-12-06","current":-6.939267,"twenty":-9.614963,"median":-6.187936,"eighty":-3.853086,"marketCap":310848901},{"date":"2024-12-13","current":-6.513871,"twenty":-9.614963,"median":-6.228039,"eighty":-3.913601,"marketCap":291793030},{"date":"2024-12-20","current":-6.487284,"twenty":-9.614963,"median":-6.236423,"eighty":-3.960049,"marketCap":290602038},{"date":"2024-12-27","current":-6.567046,"twenty":-9.614963,"median":-6.264266,"eighty":-3.986012,"marketCap":294175014},{"date":"2025-01-03","current":-7.24502,"twenty":-9.614963,"median":-6.301174,"eighty":-4.005322,"marketCap":324545309},{"date":"2025-01-10","current":-6.567046,"twenty":-9.615887,"median":-6.315834,"eighty":-4.016591,"marketCap":294175014},{"date":"2025-01-17","current":-6.43411,"twenty":-9.615887,"median":-6.331708,"eighty":-4.054488,"marketCap":288220054},{"date":"2025-01-24","current":-6.806331,"twenty":-9.615887,"median":-6.348299,"eighty":-4.07258,"marketCap":304893941},{"date":"2025-01-31","current":-6.965854,"twenty":-9.615887,"median":-6.3726,"eighty":-4.091523,"marketCap":312039893},{"date":"2025-02-07","current":-7.883114,"twenty":-9.615887,"median":-6.403592,"eighty":-4.118735,"marketCap":353129116},{"date":"2025-02-14","current":-8.627556,"twenty":-9.615887,"median":-6.428526,"eighty":-4.135241,"marketCap":386476891},{"date":"2025-02-21","current":-8.893428,"twenty":-9.615887,"median":-6.434649,"eighty":-4.158201,"marketCap":398386810},{"date":"2025-02-28","current":-5.462907,"twenty":-9.615887,"median":-6.475065,"eighty":-4.184156,"marketCap":305111221},{"date":"2025-03-07","current":-6.788543,"twenty":-9.616812,"median":-6.501051,"eighty":-4.209696,"marketCap":379149952},{"date":"2025-03-14","current":-7.387218,"twenty":-9.616812,"median":-6.513845,"eighty":-4.248803,"marketCap":412586799},{"date":"2025-03-21","current":-7.034428,"twenty":-9.616812,"median":-6.553443,"eighty":-4.299812,"marketCap":392882943},{"date":"2025-03-28","current":-7.130643,"twenty":-9.616812,"median":-6.567046,"eighty":-4.312686,"marketCap":398256722},{"date":"2025-04-04","current":-2.020527,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":112849356},{"date":"2025-04-11","current":-2.041908,"twenty":-9.615887,"median":-6.567046,"eighty":-4.32041,"marketCap":114043529},{"date":"2025-04-17","current":-2.341246,"twenty":-9.615887,"median":-6.567046,"eighty":-4.32041,"marketCap":130761952},{"date":"2025-04-25","current":-2.852608,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":159322264},{"date":"2025-05-02","current":-3.013469,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":168306602},{"date":"2025-05-09","current":-2.337851,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":130572381},{"date":"2025-05-16","current":-2.242238,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":129374470},{"date":"2025-05-23","current":-2.335664,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":134765073},{"date":"2025-05-30","current":-2.366806,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":136561940},{"date":"2025-06-06","current":-2.543279,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":146744190},{"date":"2025-06-13","current":-3.041554,"twenty":-9.616812,"median":-6.567046,"eighty":-4.330017,"marketCap":175494072},{"date":"2025-06-20","current":-3.290691,"twenty":-9.617736,"median":-6.567046,"eighty":-4.337049,"marketCap":189869013},{"date":"2025-06-27","current":-4.017342,"twenty":-9.617736,"median":-6.567046,"eighty":-4.337049,"marketCap":231795925},{"date":"2025-07-03","current":-4.463714,"twenty":-9.617736,"median":-6.567046,"eighty":-4.339848,"marketCap":257551028},{"date":"2025-07-11","current":-4.98275,"twenty":-9.617736,"median":-6.567046,"eighty":-4.359035,"marketCap":287498822},{"date":"2025-07-18","current":-5.221507,"twenty":-9.617736,"median":-6.567046,"eighty":-4.382059,"marketCap":301274807},{"date":"2025-07-25","current":-5.647117,"twenty":-9.617736,"median":-6.567046,"eighty":-4.424808,"marketCap":325831998},{"date":"2025-08-01","current":-5.179984,"twenty":-9.617736,"median":-6.567046,"eighty":-4.447844,"marketCap":298878984},{"date":"2025-08-08","current":-6.117522,"twenty":-9.617736,"median":-6.567046,"eighty":-4.457992,"marketCap":309660189},{"date":"2025-08-15","current":-6.271348,"twenty":-9.617736,"median":-6.567046,"eighty":-4.457992,"marketCap":317446616},{"date":"2025-08-22","current":-6.957646,"twenty":-9.617736,"median":-6.573101,"eighty":-4.457992,"marketCap":352186057},{"date":"2025-08-29","current":-6.933981,"twenty":-9.617736,"median":-6.584104,"eighty":-4.457992,"marketCap":350988145},{"date":"2025-09-05","current":-6.543501,"twenty":-9.61866,"median":-6.589261,"eighty":-4.456562,"marketCap":331222601},{"date":"2025-09-12","current":-6.578999,"twenty":-9.617736,"median":-6.589785,"eighty":-4.457992,"marketCap":333019469},{"date":"2025-09-19","current":-5.943039,"twenty":-9.617736,"median":-6.589785,"eighty":-4.457992,"marketCap":300828105},{"date":"2025-09-26","current":-5.871865,"twenty":-9.617736,"median":-6.589785,"eighty":-4.457992,"marketCap":297225373},{"date":"2025-10-03","current":-6.310772,"twenty":-9.617736,"median":-6.589785,"eighty":-4.457992,"marketCap":319442219},{"date":"2025-10-10","current":-6.725955,"twenty":-9.617736,"median":-6.596915,"eighty":-4.457992,"marketCap":340458155},{"date":"2025-10-17","current":-6.393809,"twenty":-9.617736,"median":-6.597717,"eighty":-4.457992,"marketCap":323645406},{"date":"2025-10-24","current":-6.144699,"twenty":-9.617736,"median":-6.597717,"eighty":-4.457992,"marketCap":311035845},{"date":"2025-10-31","current":-5.966764,"twenty":-9.617736,"median":-6.597717,"eighty":-4.457992,"marketCap":302029015},{"date":"2025-11-07","current":-6.686566,"twenty":-9.617736,"median":-6.597717,"eighty":-4.457992,"marketCap":288818999},{"date":"2025-11-14","current":-6.992121,"twenty":-9.617736,"median":-6.607245,"eighty":-4.457992,"marketCap":302017120},{"date":"2025-11-21","current":-6.588194,"twenty":-9.617736,"median":-6.622388,"eighty":-4.457992,"marketCap":284569916},{"date":"2025-11-28","current":-7.632833,"twenty":-9.617736,"median":-6.631617,"eighty":-4.457992,"marketCap":329691996},{"date":"2025-12-05","current":-6.797122,"twenty":-9.617736,"median":-6.638859,"eighty":-4.457992,"marketCap":293594332},{"date":"2025-12-10","current":-6.671765,"twenty":-9.617736,"median":-6.63393,"eighty":-4.457992,"marketCap":288179682}],"updateTime":1765480319527},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALDX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562352260","title":"Aldeyra Therapeutics Inc - No Approved Treatment for Primary Vitreoretinal Lymphoma in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2562352260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562352260?lang=en_us&edition=fundamental","pubTime":"2025-08-28 19:01","pubTimestamp":1756378860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nTUA7PQZWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2562284035","title":"Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2562284035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562284035?lang=en_us&edition=fundamental","pubTime":"2025-08-28 19:01","pubTimestamp":1756378860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nTUA7PQZWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2560933591","title":"Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2560933591","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560933591?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:01","pubTimestamp":1755601298,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. has announced that the U.S. Food and Drug Administration  has granted Fast Track Designation for its drug ADX-2191, intended for the treatment of retinitis pigmentosa. This designation is set to expedite the development and review process of ADX-2191, which has shown promising results in a Phase 2 clinical trial by improving retinal sensitivity. Retinitis pigmentosa, a severe genetic eye disease, currently lacks approved therapies for most forms. The Fast Track Designation, along with a previously announced Orphan Drug Designation, highlights the potential of ADX-2191 to meet a significant unmet need in ophthalmology. A Phase 2/3 clinical trial is anticipated to begin in 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDLc8nP6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2560193874","title":"Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected to Start in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2560193874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560193874?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:01","pubTimestamp":1755601260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nTUA8Z8ZLT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2560193801","title":"Aldeyra Therapeutics Receives Fast Track Designation for Adx‑2191 for the Treatment of Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2560193801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560193801?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:01","pubTimestamp":1755601260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nTUA8Z8ZLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2559594639","title":"Michael Alfieri, Principal Financial Officer, Reports Acquisition of Common Shares of Aldeyra Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2559594639","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559594639?lang=en_us&edition=fundamental","pubTime":"2025-08-16 04:12","pubTimestamp":1755288745,"startTime":"0","endTime":"0","summary":"Michael Alfieri, Principal Financial Officer of Aldeyra Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL2pLnpv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4139","LU1989772840.SGD","LU1989772923.USD","BK4162","ALDX","BK4588","PFG","BK4534","BK4585"],"gpt_icon":0},{"id":"2559982364","title":"Stephen Machatha, Chief Development Officer, Reports Disposal of Aldeyra Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2559982364","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559982364?lang=en_us&edition=fundamental","pubTime":"2025-08-14 06:04","pubTimestamp":1755122657,"startTime":"0","endTime":"0","summary":"Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL9KKcWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2558570480","title":"Aldeyra Therapeutics Inc  expected to post a loss of 25 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558570480","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558570480?lang=en_us&edition=fundamental","pubTime":"2025-08-09 07:34","pubTimestamp":1754696061,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc  expected to post a loss of25cents a share - Earnings Preview Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show a rise in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U03YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2557365944","title":"Aldeyra Therapeutics Unveils Innovative Therapies for Immune-Mediated and Metabolic Diseases in Latest Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2557365944","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557365944?lang=en_us&edition=fundamental","pubTime":"2025-08-05 15:49","pubTimestamp":1754380179,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. has released a presentation detailing its innovative pharmaceutical developments for immune-mediated and metabolic diseases. The company highlights its approach to modulating protein systems to optimize multiple pathways while minimizing toxicity. The presentation outlines Aldeyra's well-capitalized status and its extensive pipeline, which includes the development of Reproxalap for dry eye disease and allergic conjunctivitis, as well as other treatments for conditions such as atopic dermatitis and moderate alcohol-associated hepatitis. As of May 14, 2025, Aldeyra reported having $90.1 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL1h6y7H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2555559704","title":"Aldeyra Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2555559704","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555559704?lang=en_us&edition=fundamental","pubTime":"2025-07-29 05:26","pubTimestamp":1753737978,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Aldeyra Therapeutics Inc ALDX.OQ ALDX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nL8N3TP28I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2553039202","title":"Aldeyra Therapeutics Secures Orphan Designation from European Medicines Agency for ADX-2191 to Treat Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2553039202","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553039202?lang=en_us&edition=fundamental","pubTime":"2025-07-24 19:00","pubTimestamp":1753354844,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. has announced that the European Medicines Agency  has granted Orphan Designation for ADX-2191, their methotrexate intravitreal injection, for the treatment of inherited retinal dystrophies including retinitis pigmentosa. This regulatory milestone underscores the crucial need for effective treatments for retinitis pigmentosa, a rare genetic eye disease that affects over one million people globally. Orphan Designation by the EMA provides Aldeyra with benefits such as reduced regulatory fees and up to 10 years of market exclusivity within the European Union, aiding in the continued development and potential future availability of ADX-2191. This follows a similar Orphan Drug Designation from the U.S. FDA, highlighting the international recognition of the treatment's potential.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL6wxVw4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2553220473","title":"Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553220473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553220473?lang=en_us&edition=fundamental","pubTime":"2025-07-24 19:00","pubTimestamp":1753354800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nTUABDL5SB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2553204674","title":"Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Inherited Retinal Dystrophies Including Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2553204674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553204674?lang=en_us&edition=fundamental","pubTime":"2025-07-24 19:00","pubTimestamp":1753354800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nTUABDL5SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2552748598","title":"Aldeyra Therapeutics Announces FDA Acceptance of Reproxalap NDA for Dry Eye Disease with PDUFA Target Date Set for December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2552748598","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552748598?lang=en_us&edition=fundamental","pubTime":"2025-07-17 19:00","pubTimestamp":1752750037,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Announces FDA Acceptance of Reproxalap NDA for Dry Eye Disease with PDUFA Target Date Set for December 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on July 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL99dslz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2546099784","title":"BRIEF-Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191","url":"https://stock-news.laohu8.com/highlight/detail?id=2546099784","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546099784?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:04","pubTimestamp":1750935883,"startTime":"0","endTime":"0","summary":"BRIEF-Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191June 26 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA6KVFWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2544969286","title":"Aldeyra Therapeutics Resubmits New Drug Application for Reproxalap to FDA for Dry Eye Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2544969286","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544969286?lang=en_us&edition=fundamental","pubTime":"2025-06-17 19:00","pubTimestamp":1750158045,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc., a biotechnology company focused on developing innovative therapies for immune-mediated and metabolic diseases, has announced the resubmission of a New Drug Application  to the U.S. Food and Drug Administration  for reproxalap, an investigational drug for dry eye disease. This resubmission follows the achievement of the primary endpoint in a Phase 3 clinical trial, addressing previous methodological concerns raised by the FDA in a Complete Response Letter received in April 2025. The trial showed statistically significant results favoring reproxalap, with no notable baseline differences across treatment arms and no safety concerns. The FDA is expected to acknowledge acceptance for review within 30 days and complete the review within 6 months as per the Prescription Drug User Fee Act guidelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9Sy9Wy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2542322795","title":"Aldeyra Therapeutics Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542322795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542322795?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:02","pubTimestamp":1749672134,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc. held its annual meeting of stockholders on June 10, 2025. During the meeting, stockholders elected three directors to serve as Class II directors. The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved the compensation of the company's named executive officers on a non-binding, advisory basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2025, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5bw3G1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2539426254","title":"Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539426254","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539426254?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:01","pubTimestamp":1748516483,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc., a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference. The event is scheduled for June 5, 2025, at 4:20 p.m. ET. Todd C. Brady, M.D., Ph.D., the company's President and CEO, will engage in a conversation with Clara Dong. The live webcast will be accessible via the Investors & Media section of Aldeyra's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL8g1CXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2539404207","title":"CORRECTED-US FDA approves Alcon's new dry-eye drug (May 28)","url":"https://stock-news.laohu8.com/highlight/detail?id=2539404207","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539404207?lang=en_us&edition=fundamental","pubTime":"2025-05-29 05:42","pubTimestamp":1748468556,"startTime":"0","endTime":"0","summary":"CORRECTED-US FDA approves Alcon's new dry-eye drug  Corrects paragraph 3 in May 28 story to say \"eye drop\", not \"liquid medication\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nL3N3S01MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4139","BLCO","ALDX"],"gpt_icon":0},{"id":"2536683433","title":"Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2536683433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536683433?lang=en_us&edition=fundamental","pubTime":"2025-05-19 18:47","pubTimestamp":1747651620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 06:47 ET (10:47 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}